User Experience with an Oral Contraceptive Containing Ethinylestradiol 30g and Drospirenone 3mg (Yasmin ® ) in Clinical Practice

By Schultz-Zehden Beate  

Treatments in Endocrinology, Vol. 5, Iss. 4, 2006-01 ,pp. : 251-256

Adis International

Access to resources Recommend Favorite

Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 µg ethinyl estradiol and 3 mg drospirenone

By Milsom I.   Lete I.   Bjertnaes A.   Rokstad K.   Lindh I.   Gruber C.J.   Birkhäuser M.H.   Aubeny E.   Knudsen T.   Bastianelli C.  

Human Reproduction, Vol. 21, Iss. 9, 2006-09 ,pp. : 2304-2311

Oxford University Press

Access to resources Recommend Favorite

Ovarian function with the contraceptive vaginal ring or an oral contraceptive: a randomized study

By Duijkers Ingrid J.M.  

Human Reproduction, Vol. 19, Iss. 11, 2004-11 ,pp. : 2668-2673

Oxford University Press

Access to resources Recommend Favorite

A novel estrogen-free oral contraceptive pill for women: multicentre, double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel)

By Lakha F.   Ho P.C.   Van der Spuy Z.M.   Dada K.   Elton R.   Glasier A.F.   Critchley H.O.D.   Williams A.R.W.   Baird D.T.  

Human Reproduction, Vol. 22, Iss. 9, 2007-09 ,pp. : 2428-2436

Oxford University Press

Access to resources Recommend Favorite

A Comparison of the Cycle Control, Safety, and Efficacy Profile of a 21-Day Regimen of Ethinylestradiol 20g and Drospirenone 3mg with a 21-Day Regimen of Ethinylestradiol 20g and Desogestrel 150g

By Gruber Doris M.  

Treatments in Endocrinology, Vol. 5, Iss. 2, 2006-01 ,pp. : 115-121

Adis International

Access to resources Recommend Favorite